Lyme disease testing by large commercial laboratories in the United States

Clinical Infectious Diseases

Volumn 59, Issue 5, 2014, Pages 676-681

  Hinckley, Alison F ^a   Connally, Neeta P ^b   Meek, James I ^c   Johnson, Barbara J ^a   Kemperman, Melissa M ^d   Feldman, Katherine A ^e   White, Jennifer L ^f   Mead, Paul S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WESTERN CONNECTICUT STATE UNIVERSITY   (United States)

^c YALE UNIVERSITY   (United States)

^d MINNESOTA DEPARTMENT OF HEALTH   (United States)

^e MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^f NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Cost; Diagnostic testing; Infection; Lyme disease; United states

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ARTICLE; BACTERIUM CULTURE; CEREBROSPINAL FLUID ANALYSIS; COMMERCIAL PHENOMENA; DIAGNOSTIC TEST; ENDEMIC DISEASE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HUMAN; LABORATORY TEST; LYME DISEASE; MEDICAL LITERATURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLICATION; UNITED STATES; URINALYSIS; WESTERN BLOTTING; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; LABORATORY; QUESTIONNAIRE; STANDARDS;

BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC TESTS; LABORATORIES; LYME DISEASE; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84907420936     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu397     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 2008. Morb Mortal Wkly Rep 2010; 57:26.
2. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134. (Pubitemid 44637131)
3. Steere AC, Malawista SE, Hardin JA, Ruddy S, Askenase W, Andiman WA. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977; 86:685-98. (Pubitemid 8118762)
4. Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99:76-82. (Pubitemid 13066663)
5. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107:725-31. (Pubitemid 18041872)
6. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996; 34:1-9. (Pubitemid 126506881)
7. Halperin JJ, Luft BJ, Anand AK, et al. Lyme neuroborreliosis: central nervous system manifestations. Neurology 1989; 39:753-9. (Pubitemid 19150145)
8. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323:1438-44.
9. Pachner AR, Duray P, Steere AC. Central nervous system manifestations of Lyme disease. Arch Neurol 1989; 46:790-5. (Pubitemid 19182374)
10. Steere AC. Lyme disease. N Engl J Med 1989; 321:586-96. (Pubitemid 19212871)
11. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269:1812-6. (Pubitemid 23097348)
12. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. Morb Mortal Wkly Rep 1995; 44:590-1.
13. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005; 18:484-509. (Pubitemid 40995113)
14. Bunikis J, Barbour AG. Laboratory testing for suspected Lyme disease. Med Clin North Am 2002; 86:311-40. (Pubitemid 34327089)
15. Wormser GP, Levin A, Soman S, Adenikinju O, Longo MV, Branda JA. Comparative cost effectiveness of two-tiered testing strategies for the serodiagnosis of Lyme disease with noncutaneous manifestations. J Clin Microbiol 2013; 51:4045-9.
16. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 2009. Morb Mortal Wkly Rep 2011; 58:34.
17. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 2007. Morb Mortal Wkly Rep 2009; 56:28.
18. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187:1187-99. (Pubitemid 36438958)
19. Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, Johnson BJ, Wormser GP, Steere AC. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis 2010; 50:20-6.
20. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993; 167:392-400. (Pubitemid 23036442)
21. Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol 1995; 33:419-27.
22. Peltomaa M. The VlsE(IR6) peptide ELISA in the serodiagnosis of Lyme facial paralysis. Otol Neurotol 2004; 25:838-41. (Pubitemid 39223265)
23. Wormser GP, Schriefer M, Aguero-Rosenfeld ME, et al. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 2013; 75:9-15.
24. Johnson BJ, Robbins KE, Bailey RE, et al. Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. J Infect Dis 1996; 174:346-53. (Pubitemid 26251421)
25. Ramsey AH, Belongia EA, Chyou PH, Davis JP. Appropriateness of Lyme disease serologic testing. Ann Fam Med 2004; 2:341-4. (Pubitemid 39107891)
26. Migliara/Kaplan Associates. Projected annual market for rapid direct tests. Rapid testing for infectious diseases: competitive advantage in a turbulent market. Owings Mills, MD: Migliara/Kaplan, 1993:277.
27. Strickland GT, Karp AC, Mathews A, Pena CA. Utilization and cost of serologic tests for Lyme disease in Maryland. J Infect Dis 1997; 176:819-21. (Pubitemid 27360561)
28. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 2011; 53:541-7.
29. Meek JI, Roberts CL, Smith EV Jr, Cartter ML. Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manag Pract 1996; 2:61-5.
30. Naleway AL, Belongia EA, Kazmierczak JJ, Greenlee RT, Davis JP. Lyme disease incidence in Wisconsin: a comparison of state-reported rates and rates from a population-based cohort. Am J Epidemiol 2002; 155:1120-7. (Pubitemid 34625501)
31. Orloski KA, Campbell GL, Genese CA, et al. Emergence of Lyme disease in Hunterdon County, New Jersey, 1993: a case-control study of risk factors and evaluation of reporting patterns. Am J Epidemiol 1998; 147:391-7. (Pubitemid 28106894)
32. Young JD. Underreporting of Lyme disease. N Engl J Med 1998; 338:1629.
33. Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol 1994; 32:1519-25. (Pubitemid 24179386)
34. Qaseem A, Alguire P, Dallas P, et al. Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care. Ann Intern Med 2012; 156:147-9.
35. Trevejo RT, Krause PJ, Sikand VK, et al. Evaluation of two-test serodiagnostic method for early Lyme disease in clinical practice. J Infect Dis 1999; 179:931-8. (Pubitemid 29159339)
36. Fix AD, Strickland GT, Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. JAMA 1998; 279:206-10. (Pubitemid 28133782)
37. Tugwell P, Dennis DT, Weinstein A, et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997; 127:1109-23. (Pubitemid 28012083)
38. Porwancher R. A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease. J Infect Dis 1999; 179:1021-4. (Pubitemid 29159352)
39. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995; 171:356-61.